On May 26, 2020, Diffusion Pharmaceuticals announced it had received an accelerated response from the FDA to the Companyﾒs Pre-Investigational New Drug (PIND) meeting request. The PIND was filed Apr. 27, seeking FDA guidance on the Companyﾒs proposed clinical development program for the use of trans sodium crocetinate in COVID-19 patients displaying severe respiratory symptoms and low oxygen levels.